- Home
- OTLK vs IPWR Comparison
OTLK vs IPWR Comparison
Compare OTLK & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- IPWR
- Stock Information
- Founded
- OTLK 2010
- IPWR 2007
- Country
- OTLK United States
- IPWR United States
- Employees
- OTLK N/A
- IPWR N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- IPWR Industrial Machinery/Components
- Sector
- OTLK Health Care
- IPWR Industrials
- Exchange
- OTLK Nasdaq
- IPWR Nasdaq
- Market Cap
- OTLK 48.3M
- IPWR 52.8M
- IPO Year
- OTLK 2016
- IPWR 2013
- Fundamental
- Price
- OTLK $1.09
- IPWR $5.17
- Analyst Decision
- OTLK Buy
- IPWR Hold
- Analyst Count
- OTLK 5
- IPWR 1
- Target Price
- OTLK $8.50
- IPWR N/A
- AVG Volume (30 Days)
- OTLK 8.2M
- IPWR 43.8K
- Earning Date
- OTLK 08-14-2025
- IPWR 11-13-2025
- Dividend Yield
- OTLK N/A
- IPWR N/A
- EPS Growth
- OTLK N/A
- IPWR N/A
- EPS
- OTLK N/A
- IPWR N/A
- Revenue
- OTLK $1,505,322.00
- IPWR $19,240.00
- Revenue This Year
- OTLK N/A
- IPWR N/A
- Revenue Next Year
- OTLK $484.88
- IPWR $9,900.00
- P/E Ratio
- OTLK N/A
- IPWR N/A
- Revenue Growth
- OTLK N/A
- IPWR N/A
- 52 Week Low
- OTLK $0.79
- IPWR $3.77
- 52 Week High
- OTLK $7.26
- IPWR $8.85
- Technical
- Relative Strength Index (RSI)
- OTLK 37.49
- IPWR 53.59
- Support Level
- OTLK $1.02
- IPWR $4.97
- Resistance Level
- OTLK $1.19
- IPWR $5.50
- Average True Range (ATR)
- OTLK 0.22
- IPWR 0.33
- MACD
- OTLK -0.04
- IPWR 0.01
- Stochastic Oscillator
- OTLK 11.18
- IPWR 40.51
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About IPWR Ideal Power Inc.
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.